Form 4: PTC Therapeutics CFO Sells Shares to Cover Tax Obligations

PTC Therapeutics' Chief Financial Officer, Pierre Gravier, sold 2,516 shares of common stock at $49.46 per share to satisfy tax withholding obligations related to RSU vesting.

Summary

• Pierre Gravier, Chief Financial Officer of PTC Therapeutics, Inc. (PTCT), sold 2,516 shares of common stock.
• The transaction occurred on July 15, 2025, at a price of $49.46 per share.
• The sale was an automatic "sell to cover" election to satisfy tax withholding obligations.
• This sale was in connection with the vesting of 6,500 Restricted Stock Units (RSUs) from a larger grant of 26,000 RSUs made on July 13, 2023.
• Following this transaction, Pierre Gravier beneficially owns 71,920 shares of common stock directly.
• The transaction was made pursuant to a Rule 10b5-1(c) plan, indicating a pre-arranged sale.

Sentiment

Score: 5

Explanation: The transaction is a routine 'sell to cover' for tax purposes related to RSU vesting, which is a neutral event and does not indicate a change in management's outlook or confidence in the company.

Positives

• The transaction is a routine "sell to cover" for tax purposes, which is a common and expected event for RSU vesting and does not necessarily indicate a lack of confidence in the company.
• The transaction was executed under a Rule 10b5-1 plan, demonstrating a pre-arranged, non-discretionary sale.

Negatives

• No inherent negatives beyond the reduction in the CFO's direct shareholding due to tax obligations.

Industry Context

This is a routine insider transaction for tax purposes, common across all industries for executives receiving equity compensation. It does not reflect broader industry trends.

Comparison to Industry Standards

• This type of "sell to cover" transaction is standard practice for executives across publicly traded companies globally when equity awards vest, particularly for Restricted Stock Units (RSUs), to manage tax liabilities. There are no specific comparable companies or projects mentioned to assess against.

Stakeholder Impact

• Shareholders: A minor, routine reduction in insider ownership due to tax obligations. Generally, this type of transaction has minimal impact on shareholder sentiment or share price.

Key Dates

Keywords

PTC Therapeutics, PTCT, Form 4, SEC filing, insider trading, stock sale, Restricted Stock Units, RSU vesting, sell to cover, tax withholding, Pierre Gravier, Chief Financial Officer, CFO, Rule 10b5-1